Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Weber

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Endocrine Pathology|February 18, 2019
Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination PathwayMarta Szybowska, Ozgur Mete, Evan Weber, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 10, 2024
Alternative immune effector cells picking up speedEvan Weber, Marie Bleakley, James C Cronk, et al.
Current Oncology (Toronto, Ont.)|May 27, 2022
Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian CancerMichaela Bercovitch Sadinsky, Joanne Power, Enza Ambrosio, et al.
Current Oncology (Toronto, Ont.)|January 20, 2021
Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian CohortJessica Lawrence, Lara Richer, Jocelyne Arseneau, et al.
JID Innovations : Skin Science From Molecules to Population Health|January 19, 2026
Deep intronic <i>MSH2</i> variant confirms Muir-Torre subtype of Lynch syndromeFiona Chan-Pak-Choon, Andrew Y Shuen, Evan Weber, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|July 3, 2026
The Impact of Pathogenic Variants of BRCA1, BRCA2 and Other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors - Single Center Experience from QuebecXing Zeng, Gabriel Levin, Lawrie Shabazian, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Rapid Assessment of Immune Effector Cell-mediated Cytotoxicity using mRNA Lipid NanoparticlesPhilip Mollica, Jian Li, Sang-Hoon Kim, et al.
Pediatric Blood & Cancer|September 13, 2018
"A change in perspective": Exploring the experiences of adolescents with hereditary tumor predispositionEvan Weber, Cheryl Shuman, Jonathan D Wasserman, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Transient EZH2 suppression by Tazemetostat during <i>in vitro</i> expansion maintains T cell stemness and improves adoptive T cell therapyYingqin Hou, Jaroslav Zak, Yujie Shi, et al.
Frontiers in Immunology|May 27, 2026
Rapid assessment of immune effector cell-mediated cytotoxicity using mRNA lipid nanoparticlesPhilip Mollica, Jian Li, Sang-Hoon Kim, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Endocrine Pathology|February 18, 2019
Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination PathwayMarta Szybowska, Ozgur Mete, Evan Weber, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 10, 2024
Alternative immune effector cells picking up speedEvan Weber, Marie Bleakley, James C Cronk, et al.
Current Oncology (Toronto, Ont.)|May 27, 2022
Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian CancerMichaela Bercovitch Sadinsky, Joanne Power, Enza Ambrosio, et al.
Current Oncology (Toronto, Ont.)|January 20, 2021
Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian CohortJessica Lawrence, Lara Richer, Jocelyne Arseneau, et al.
JID Innovations : Skin Science From Molecules to Population Health|January 19, 2026
Deep intronic <i>MSH2</i> variant confirms Muir-Torre subtype of Lynch syndromeFiona Chan-Pak-Choon, Andrew Y Shuen, Evan Weber, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|July 3, 2026
The Impact of Pathogenic Variants of BRCA1, BRCA2 and Other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors - Single Center Experience from QuebecXing Zeng, Gabriel Levin, Lawrie Shabazian, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Rapid Assessment of Immune Effector Cell-mediated Cytotoxicity using mRNA Lipid NanoparticlesPhilip Mollica, Jian Li, Sang-Hoon Kim, et al.
Pediatric Blood & Cancer|September 13, 2018
"A change in perspective": Exploring the experiences of adolescents with hereditary tumor predispositionEvan Weber, Cheryl Shuman, Jonathan D Wasserman, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Transient EZH2 suppression by Tazemetostat during <i>in vitro</i> expansion maintains T cell stemness and improves adoptive T cell therapyYingqin Hou, Jaroslav Zak, Yujie Shi, et al.
Frontiers in Immunology|May 27, 2026
Rapid assessment of immune effector cell-mediated cytotoxicity using mRNA lipid nanoparticlesPhilip Mollica, Jian Li, Sang-Hoon Kim, et al.
Pageof 3